NCT06136351 is a Phase 2 clinical trial of Zanubrutinib in Lymphoma, Mantle-Cell, sponsored by Ruijin Hospital.

Who is sponsoring NCT06136351?

NCT06136351 is sponsored by Ruijin Hospital.

What drugs are being tested in NCT06136351?

Interventions in NCT06136351: Zanubrutinib, Rituximab, Bendamustin.

What condition does NCT06136351 study?

NCT06136351 studies Lymphoma, Mantle-Cell.

Is NCT06136351 still recruiting?

NCT06136351 is currently recruiting now. Last updated 29 November 2023.

Last reviewed 2023-11-29 · How we verify

NCT06136351

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

Recruiting now Phase 2 Last updated 29 November 2023

What this trial tests

Phase 2 trial testing Zanubrutinib in Lymphoma, Mantle-Cell in 23 participants. Currently enrolling.

Timeline

15 November 2023

Primary endpoint
1 November 2027

1 November 2027

Quick facts

Lead sponsor	Ruijin Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	23
Start date	15 November 2023
Primary completion	1 November 2027
Estimated completion	1 November 2027
Sites	1 location across China

Drugs / interventions tested

Zanubrutinib (ZANUBRUTINIB) — full drug profile →
Rituximab — full drug profile →
Bendamustin — full drug profile →

Conditions studied

Lymphoma, Mantle-Cell — all drugs for Lymphoma, Mantle-Cell →

Sponsor

Ruijin Hospital

Who can join

18 and older, any sex, with Lymphoma, Mantle-Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of Zanubrutinib given in combination with bendamustine and rituximab in (elderly or TP53 alterations or chemotherapy intolerance) patients with newly diagnosed mantle cell lymphoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Zanubrutinib

Trials testing the same drug.

NCT07341191 — Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR · Phase 2 · not yet recruiting
NCT06859008 — Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Rel · Phase 1 · recruiting
NCT07377578 — A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cel · Phase 3 · recruiting
NCT07321652 — Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated C · Phase 3 · not yet recruiting
NCT07283965 — Zanubrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies · not yet recruiting

Other recruiting trials for Lymphoma, Mantle-Cell

Currently open trials in the same condition.

NCT05659732 — A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer · Phase 1 · recruiting

Other Ruijin Hospital trials

Trials by the same sponsor.

NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06136351 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
Last refreshed: 29 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06136351.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing